The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Non-Helicobacter pylori, Non-NSAID Peptic Ulcer Disease

Non-Helicobacter pylori, Non-NSAIDs 소화성궤양

  • Rew, Jong-Sun (Department of Internal Medicine, Chonnam National University Medical School)
  • 류종선 (전남대학교 의과대학 내과학교실)
  • Published : 2014.06.01
⟨ Previous Next ⟩

Abstract

Non-Helicobacter pylori, non-NSAID peptic ulcer disease, termed idiopathic peptic ulcer disease (IPUD), is being increasingly recognized. Current data suggest that the relative proportion of patients with IPUD among those with peptic ulcers has been increasing for the past decade in both the West and East, while the prevalence of H. pylori ulcers has decreased. Potential causative or risk factors of IPUD include cigarette smoking, genetic predisposition, psychological factors, infections other than H. pylori, non-NSAID drugs or toxins, systemic inflammatory disease, and local mucosal defects. Diagnosis is made after confident exclusion of H. pylori infection by at least two different standard tests and accurate exclusion of unrecognized or surreptitious NSAID use by careful history taking and serologic assay. IPUD is characterized by higher complication and recurrence rates than other forms of peptic ulcer disease and has become a main cause of refractory ulcer disease. Maintenance therapy using proton pump inhibitors may be required at higher doses and for longer durations than in H. pylori- or NSAID-associated peptic ulcer diseases. Well-designed nationwide epidemiologic studies are required to fully elucidate this emerging condition.

Keywords

References

  1. Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995;9(Suppl 2):59-69.
  2. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet 2009;374:1449-1461. https://doi.org/10.1016/S0140-6736(09)60938-7
  3. Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating Helicobacter pylori and reducing ulcer recurrence: RBC Helicobacter pylori Study Group. Aliment Pharmacol Ther 1996;10:251-261. https://doi.org/10.1111/j.0953-0673.1996.00251.x
  4. Jyotheeswaran S, Shah AN, Jin HO, Potter GD, Ona FV, Chey WY. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol 1998;93:574-578. https://doi.org/10.1111/j.1572-0241.1998.167_b.x
  5. Ciociola AA, McSorley DJ, Turner K, Sykes D, Palmer JB. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999;94:1834-1840. https://doi.org/10.1111/j.1572-0241.1999.01214.x
  6. Boulos PB, Botha A, Hobsley M, Holton J, Oshowo AO, Tovey FI. Possible absence of Helicobacter pylori in the early stages of duodenal ulceration. QJM 2002;95:749-752. https://doi.org/10.1093/qjmed/95.11.749
  7. Jang HJ, Choi MH, Shin WG, et al. Has peptic ulcer disease changed during the past ten years in Korea? a prospective multi-center study. Dig Dis Sci 2008;53:1527-1531. https://doi.org/10.1007/s10620-007-0028-6
  8. Kang JM, Seo PJ, Kim N, et al. Analysis of direct medical care costs of peptic ulcer disease in a Korean tertiary medical center. Scand J Gastroenterol 2012;47:36-42. https://doi.org/10.3109/00365521.2011.639083
  9. Yoon H, Kim SG, Jung HC, Song IS. High recurrence rate of idiopathic peptic ulcers in long-term follow-up. Gut Liver 2013;7:175-181. https://doi.org/10.5009/gnl.2013.7.2.175
  10. Bytzer P, Teglbjaerg PS; Danish Ulcer Study Group. Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis: results from a randomized trial with 2-year follow-up. Am J Gastroenterol 2001;96:1409-1416.
  11. Xia HH, Wong BC, Wong KW, et al. Clinical and endoscopic characteristics of non-Helicobacter pylori, non-NSAID duodenal ulcers: a long-term prospective study. Aliment Pharmacol Ther 2001;15:1875-1882. https://doi.org/10.1046/j.1365-2036.2001.01115.x
  12. Hung LC, Ching JY, Sung JJ, et al. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology 2005;128:1845-1850. https://doi.org/10.1053/j.gastro.2005.03.026
  13. Wong GL, Wong VW, Chan Y, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 2009;137:525-531. https://doi.org/10.1053/j.gastro.2009.05.006
  14. Jang MK, Kim HY, Cho BD, et al. Prospective study for the prevalence of Helicobacter pylori infection in patients with gastric ulcer and duodenal ulcer among Korean population. Korean J Med 1997;52:457-465.
  15. Park DH. Peptic ulcer diseases in Korea. Korean J Med 1998;55:437-445.
  16. Kim JJ, Kim N, Park HK, et al. Clinical characteristics of patients diagnosed as peptic ulcer disease in the third referral center in 2007. Korean J Gastroenterol 2012;59:338-346. https://doi.org/10.4166/kjg.2012.59.5.338
  17. Chung IS, Kim BW. Peptic ulcer disease in Korea. Korean J Helicobacter Up Gastrointest Res 2012;12:19-22. https://doi.org/10.7704/kjhugr.2012.12.1.19
  18. Kim JS, Kim BW. Epidemiology of peptic ulcer disease in Korea. Korean J Helicobacter Up Gastrointest Res 2014;14:1-5. https://doi.org/10.7704/kjhugr.2014.14.1.1
  19. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007;12:333-340. https://doi.org/10.1111/j.1523-5378.2007.00504.x
  20. Kim JI, Kim SG, Kim N, et al. Changing prevalence of upper gastrointestinal disease in 28 893 Koreans from 1995 to 2005. Eur J Gastroenterol Hepatol 2009;21:787-793. https://doi.org/10.1097/MEG.0b013e32830e285a
  21. Arroyo MT, Forne M, de Argila CM, et al. The prevalence of peptic ulcer not related to Helicobacter pylori or nonsteroidal anti-inflammatory drug use is negligible in southern Europe. Helicobacter 2004;9:249-254. https://doi.org/10.1111/j.1083-4389.2004.00219.x
  22. Nishikawa K, Sugiyama T, Kato M, et al. Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol 2000;12:635-640. https://doi.org/10.1097/00042737-200012060-00010
  23. Sugiyama T, Nishikawa K, Komatsu Y, et al. Attributable risk of Helicobacter pylori in peptic ulcer disease: does declining prevalence of infection in general population explain increasing frequency of non-Helicobacter pylori ulcers? Dig Dis Sci 2001;46:307-310. https://doi.org/10.1023/A:1005600831851
  24. Tan HJ, Goh KL. Changing epidemiology of Helicobacter pylori in Asia. J Dig Dis 2008;9:186-189. https://doi.org/10.1111/j.1751-2980.2008.00344.x
  25. Iijima K, Kanno T, Koike T, Shimosegawa T. Helicobacter pylori-negative, non-steroidal anti-inflammatory drug: negative idiopathic ulcers in Asia. World J Gastroenterol 2014;20:706-713. https://doi.org/10.3748/wjg.v20.i3.706
  26. Quan C, Talley NJ. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Am J Gastroenterol 2002;97:2950-2961. https://doi.org/10.1111/j.1572-0241.2002.07068.x
  27. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer: nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997;24:2-17. https://doi.org/10.1097/00004836-199701000-00002
  28. Korman MG, Hansky J, Eaves ER, Schmidt GT. Influence of cigarette smoking on healing and relapse in duodenal ulcer disease. Gastroenterology 1983;85:871-874.
  29. Friedman GD, Siegelaub AB, Seltzer CC. Cigarettes, alcohol, coffee and peptic ulcer. N Engl J Med 1974;290:469-473. https://doi.org/10.1056/NEJM197402282900901
  30. Cryer B, Redfern JS, Goldschmiedt M, Lee E, Feldman M. Effect of aging on gastric and duodenal mucosal prostaglandin concentrations in humans. Gastroenterology 1992;102(4 Pt 1):1118-1123. https://doi.org/10.1016/0016-5085(92)90746-L
  31. McColl KE, el-Nujumi AM, Chittajallu RS, et al. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut 1993;34:762-768. https://doi.org/10.1136/gut.34.6.762
  32. Clarke CA, Evans DA, McConnell RB, Sheppard PM. Secretion of blood group antigens and peptic ulcer. Br Med J 1959;1:603-607. https://doi.org/10.1136/bmj.1.5122.603
  33. Peters MN, Richardson CT. Stressful life events, acid hypersecretion, and ulcer disease. Gastroenterology 1983;84:114-119.
  34. Raiha I, Kemppainen H, Kaprio J, Koskenvuo M, Sourander L. Lifestyle, stress, and genes in peptic ulcer disease: a nationwide twin cohort study. Arch Intern Med 1998;158:698-704. https://doi.org/10.1001/archinte.158.7.698
  35. Sinar DR, Bozymski EM, Blackshear JL. Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo. Clin Ther 1986;8:157-163.
  36. Graham DY, Malaty HM. Alendronate gastric ulcers. Aliment Pharmacol Ther 1999;13:515-519. https://doi.org/10.1046/j.1365-2036.1999.00488.x
  37. Sharma R, Organ CH Jr, Hirvela ER, Henderson VJ. Clinical observation of the temporal association between crack cocaine and duodenal ulcer perforation. Am J Surg 1997;174:629-632. https://doi.org/10.1016/S0002-9610(97)00215-8
  38. Doria MI Jr, Doria LK, Faintuch J, Levin B. Gastric mucosal injury after hepatic arterial infusion chemotherapy with floxuridine: a clinical and pathologic study. Cancer 1994;73:2042-2047. https://doi.org/10.1002/1097-0142(19940415)73:8<2042::AID-CNCR2820730805>3.0.CO;2-A
  39. Goddard AF, Logan RP, Atherton JC, Jenkins D, Spiller RC. Healing of duodenal ulcer after eradication of Helicobacter heilmannii. Lancet 1997;349:1815-1816.
  40. Arnar DO, Gudmundsson G, Theodors A, Valtysson G, Sigfusson A, Jonasson JG. Primary cytomegalovirus infection and gastric ulcers in normal host. Dig Dis Sci 1991;36:108-111. https://doi.org/10.1007/BF01300097
  41. Lohr JM, Nelson JA, Oldstone MB. Is herpes simplex virus associated with peptic ulcer disease? J Virol 1990;64:2168-2174.
  42. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727-734. https://doi.org/10.1056/NEJM199803123381105
  43. Borody TJ, George LL, Brandl S, Andrews P, Jankiewicz E, Ostapowicz N. Smoking does not contribute to duodenal ulcer relapse after Helicobacter pylori eradication. Am J Gastroenterol 1992;87:1390-1393.
  44. Endoh K, Leung FW. Effects of smoking and nicotine on the gastric mucosa: a review of clinical and experimental evidence. Gastroenterology 1994;107:864-878. https://doi.org/10.1016/0016-5085(94)90138-4
  45. Eastwood GL. Is smoking still important in the pathogenesis of peptic ulcer disease? J Clin Gastroenterol 1997;25(Suppl 1):S1-7. https://doi.org/10.1097/00004836-199700001-00003
  46. Malaty HM, Graham DY, Isaksson I, Engstrand L, Pedersen NL. Are genetic influences on peptic ulcer dependent or independent of genetic influences for Helicobacter pylori infection? Arch Intern Med 2000;160:105-109. https://doi.org/10.1001/archinte.160.1.105
  47. Zheng PY, Hua J, Yeoh KG, Ho B. Association of peptic ulcer with increased expression of Lewis antigens but not cagA, iceA, and vacA in Helicobacter pylori isolates in an Asian population. Gut 2000;47:18-22. https://doi.org/10.1136/gut.47.1.18
  48. Feldman M, Walker P, Green JL, Weingarden K. Life events stress and psychosocial factors in men with peptic ulcer disease: a multidimensional case-controlled study. Gastroenterology 1986;91:1370-1379. https://doi.org/10.1016/0016-5085(86)90189-7
  49. Hui WM, Shiu LP, Lok AS, Lam SK. Life events and daily stress in duodenal ulcer disease: a prospective study of patients with active disease and in remission. Digestion 1992;52:165-172. https://doi.org/10.1159/000200949
  50. Freston JW. Helicobacter pylori-negative peptic ulcers: frequency and implications for management. J Gastroenterol 2000;35(Suppl 12):29-32.
  51. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-973. https://doi.org/10.1056/NEJM200103293441304
  52. Arora OP, Kapoor CP, Sobti P. Study of gastroduodenal abnormalities in chronic bronchitis and emphysema. Am J Gastroenterol 1968;50:289-296.
  53. Liang CC, Muo CH, Wang IK, et al. Peptic ulcer disease risk in chronic kidney disease: ten-year incidence, ulcer location, and ulcerogenic effect of medications. PLos One 2014;9:e87952. https://doi.org/10.1371/journal.pone.0087952
  54. Andriulli A, Arrigoni A, Gindro T, Verme G. Prevalence of peptic ulcer in patients with various hepatopathies. Minerva Med 1986;77:1801-1805.
  55. Fraser AG, Pounder RE, Burroughs AK. Gastric secretion and peptic ulceration in cirrhosis. J Hepatol 1993;19:171-182. https://doi.org/10.1016/S0168-8278(05)80191-6
  56. Loginov AS, Zvenigorodskaia LA, Potapova VB, Arbuzova VG, Korzhikov VV, Nilova TV. The characteristics of peptic ulcer in subjects with concomitant ischemic heart disease. Ter Arkh 1998;70:9-13.
  57. Gasparoni P, Caroli A, Sardeo G, Maschio S, Lo Giudice C, Fioretti D. Primary hyperparathyroidism and peptic ulcer. Minerva Med 1989;80:1327-1330.
  58. Fielding JF, Cooke WT. Peptic ulceration in Crohn's disease (reional enteritis). Gut 1970;11:998-1000. https://doi.org/10.1136/gut.11.12.998
  59. Callaghan J, Brown S, Battcock T, Parry S, Snook J. Aggressive Helicobacter pylori-negative peptic ulceration as the initial manifestation of Crohn's disease. Frontline Gastroenterol 2012;3:201-205. https://doi.org/10.1136/flgastro-2012-100126
  60. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine (Baltimore) 2000;79:379-411. https://doi.org/10.1097/00005792-200011000-00004
  61. Cherner JA, Jensen RT, Dubois A, O'Dorisio TM, Gardner JD, Metcalfe DD. Gastrointestinal dysfunction in systemic mastocytosis: a prospective study. Gastroenterology 1988;95:657-667. https://doi.org/10.1016/S0016-5085(88)80012-X
  62. Urayama S, Kozarek R, Ball T, et al. Presentation and treatment of annular pancreas in an adult population. Am J Gastroenterol 1995;90:995-999.
  63. Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009;30:791-815. https://doi.org/10.1111/j.1365-2036.2009.04105.x
  64. Chey WD, Woods M, Scheiman JM, Nostrant TT, DelValle J. Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism. Am J Gastroenterol 1997;92:446-450.
  65. Dickey W, Kenny BD, McConnell JB. Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies. Aliment Pharmacol Ther 1996;10:289-293. https://doi.org/10.1111/j.0953-0673.1996.00289.x
  66. Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997;112:683-689. https://doi.org/10.1053/gast.1997.v112.pm9041228
  67. Laine L, Cohen H. Helicobacter pylori: drowning in a pool of blood? Gastrointest Endosc 1999;49(3 Pt 1):398-402. https://doi.org/10.1016/S0016-5107(99)70024-6
  68. Farinati F, Valiante F, Germanà B, et al. Prevalence of Helicobacter pylori infection in patients with precancerous changes and gastric cancer. Eur J Cancer Prev 1993;2:321-326. https://doi.org/10.1097/00008469-199307000-00006
  69. Bayerdorffer E, Oertel H, Lehn N, et al. Topographic association between active gastritis and Campylobacter pylori colonisation. J Clin Pathol 1989;42:834-839. https://doi.org/10.1136/jcp.42.8.834
  70. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis: the updated Sydney System: International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-1181.
  71. Hirschowitz BI, Lanas A. Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. Gastroenterology 1998;114:883-892. https://doi.org/10.1016/S0016-5085(98)70307-5
  72. Benya RV, Metz DC, Venzon DJ, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I. Am J Med 1994;97:436-444. https://doi.org/10.1016/0002-9343(94)90323-9
  73. Prinz RA. Localization of gastrinomas. Int J Pancreatol 1996;19:79-91.
  74. Gillen D, Wirz AA, Neithercut WD, Ardill JE, McColl KE. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 1999;44:468-475. https://doi.org/10.1136/gut.44.4.468
  75. Sonnenberg A, Muller-Lissner SA, Vogel E, et al. Predictors of duodenal ulcer healing and relapse. Gastroenterology 1981;81:1061-1067.